Grifols approves subsidiary to make public delisting purchase offer to Biotest

The Board of Directors of the Grifols (GRFS), S.A. has unanimously approved that its fully owned subsidiary Grifols Biotest Holdings GmbH, to make a public delisting purchase offer to the shareholders of Biotest AG. Grifols Biotest Holdings GmbH will offer all no-par bearer common shares of Biotest and all non-voting bearer preferred shares in Biotest and its intention to EUR 43.00 per common share and EUR 30.00 per preferred share of Biotest. Furthermore, the Grifols and Biotest have agreed to jointly apply for the cancellation of Biotest’s shares from trading on the Frankfurt Securities Exchange.